Developing a Personalized Cancer Nanovaccine Using Coxsackievirus-Reprogrammed Cancer Cell Membranes for Enhanced...

Area of Science:

• Immunotherapy
• Nanotechnology
• Oncology

Background:

• Cancer vaccines show promise but face challenges from tumor immunosuppression, such as PD-L1.
• Developing strategies to overcome immune evasion is critical for effective cancer immunotherapy.

Purpose of the Study:

• To develop and evaluate a personalized nanovaccine (PLGA@hdCVB3I4T1M) to enhance antitumor immune responses.
• To investigate the mechanisms by which the nanovaccine modulates the tumor microenvironment and stimulates anti-cancer immunity.

Main Methods:

• Fabrication of PLGA nanoparticles encapsulating heat-deactivated Coxsackievirus B3 (hdCVB3) and 4T1 breast cancer cell membranes.
• RNA sequencing and protein analysis to assess immune gene and protein expression.
• In vitro and in vivo studies in animal models to evaluate safety, efficacy, and immune cell infiltration.

Main Results:

• The nanovaccine significantly reduced immunosuppressive markers (PD-L1, B7-H3, CD47) and increased immunostimulatory proteins (calreticulin).
• PLGA@hdCVB3I4T1M demonstrated potent immunostimulatory effects, enhancing immune cell infiltration and cytokine production.
• The nanovaccine achieved significant tumor suppression, prolonged survival, and amplified immune recognition of tumor antigens, especially when combined with oncolytic virotherapy.

Conclusions:

• PLGA@hdCVB3I4T1M is a safe and effective nanovaccine that stimulates a robust antitumor immune response by overcoming tumor immune evasion.
• This nanovaccine strategy holds significant potential for clinical translation in cancer immunotherapy, particularly in combination therapies.